Please ensure Javascript is enabled for purposes of website accessibility

How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?

By Keith Speights and Brian Orelli, PhD - Apr 10, 2021 at 9:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biotech is getting critical help from a big pharma company.

GlaxoSmithKline (GSK -0.23%) has teamed up with several other companies to develop COVID-19 vaccine candidates. However, the big drugmaker is also helping support the manufacturing of Novavax's (NVAX -2.93%) COVID-19 vaccine -- a vaccine for which it was completely uninvolved in the development. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how important this manufacturing deal with GlaxoSmithKline is for Novavax.

Keith Speights: Novavax -- the ticker there is NVAX -- announced this week that it's teamed up with GlaxoSmithKline -- ticker there is GSK -- to support the manufacturing of its COVID vaccine in the United Kingdom. GlaxoSmithKline is going to make up to 60 million doses, or to help make up to 60 million doses, there's a key there. How important Brian, do you think this news is for Novavax?

Brian Orelli: Glaxo isn't actually making the drug product, that's being done by Novavax's contract manufacturers which is Fujifilm Diosynth Biotechnologies, and Glaxo is actually just putting it in the bottles, putting the stoppers on, slapping on the label, putting in a box, and sending on its way, so that's called fill and finish. It's a routine step, but certainly, obviously, a necessarily one.

Then we've heard reports about Novavax having trouble sourcing supplies specifically for the fill and finish step, and so it seems like it could benefit Novavax substantially if those reports were true, that the main issue is that fill finish step and now they have a lot of help for the fill and finish.

This seems like the UK government got involved I think in this deal. It feels like this might be tied to the back and forth with Novavax and the EU contract. The drug is being made by a contractor in the UK, and then Glaxo, of course, is a UK company, and the plant that they're going to fill it in, is in the EU.

This may be the UK trying to keep the vaccine away from the European Union or at least keep the European Union from doing the last step in filling it, and not giving any back to the United Kingdom if they need it. I think there may be some government play here as well it's just Novavax gets a fill and finish contractor.

Speights: Brian, I'm shocked, shocked I tell you that you're saying politics could be involved here.

Orelli: Yeah.

Speights: [laughs] So this is good news for Novavax overall, right?

Orelli: Yeah, I mean, I would say. Definitely, I don't think Novavax had a way of building a plant and filling and finishing their own stuff that quickly as compared to just getting Glaxo to open up some space in their plant to do it. So yes, I think it's definitely good news for Novavax.

Brian Orelli, PhD owns shares of Novavax. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends GlaxoSmithKline. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$36.09 (-2.93%) $-1.09
GSK Stock Quote
GSK
GSK
$34.17 (-0.23%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.